Intravenous Ribavirin Protocol to Treat Individuals With Viral Hemorrhagic Fever
This study aims to see if an intravenous (IV) medicine called Ribavirin can help people with a suspected or confirmed case of viral hemorrhagic fever, specifically Crimean-Congo hemorrhagic fever or Lassa fever. These are serious viral infections. The study wants to investigate if giving Ribavirin directly into the bloodstream is a good treatment option. Participants would be carefully monitored, and their health would be tracked over time. The goal is to understand if Ribavirin can improve outcomes for those affected by these challenging illnesses. This research is important for finding effective ways to manage severe viral infections.
At a glance
What is this study about?
Imagine you or someone you know might have a very serious viral infection, like Crimean-Congo hemorrhagic fever or Lassa fever. These illnesses can be very serious and need urgent medical attention. Currently, doctors are looking for the best ways to treat them. This study is designed to explore whether a medicine called Ribavirin, given through a drip into your arm (intravenously), could be a helpful treatment option.
Ribavirin is a medicine that has been used before to fight certain viruses. In this study, doctors want to see if it can make a difference for people who are strongly suspected of having, or are confirmed to have, one of these specific viral hemorrhagic fevers. The study aims to gather important information that could help doctors in the future decide the best way to care for patients with these challenging conditions.
Taking part in this study would mean receiving Ribavirin if you fit the criteria, and doctors would closely watch your health. This kind of research is vital because it helps us learn more about these rare but dangerous diseases and how to best treat them. Always remember, the decision to participate in any study is entirely yours, and you should discuss it thoroughly with your doctor.
Key takeaways
- This study is testing Ribavirin for serious viral infections.
- It's for specific viral hemorrhagic fevers like Crimean-Congo or Lassa fever.
- Ribavirin would be given directly into a vein.
- Eligibility includes age and connection to military medical facilities.
- Close monitoring and follow-up appointments are required.
- Discuss all risks and benefits with your doctor.
Who may be eligible?
To join this study, you would need to be between 18 and 65 years old (or 17 if you are in the military). You must also be thought to have, or have been diagnosed with, Crimean-Congo hemorrhagic fever or Lassa fever. This study is open to military personnel, their families, and others connected to the US military, as well as allied military forces and local people who can access their medical facilities.
There are also some health checks. For example, your blood count needs to be above a certain level. You cannot join if you already know you react badly to Ribavirin, or if you have certain blood conditions like sickle-cell anemia. Also, if you're very, very unwell and not getting better quickly with other support, this study might not be suitable.
If you're a woman who could become pregnant, you'll need a pregnancy test. If it's negative, you must agree to prevent pregnancy during the study and for 7 months afterwards. Men in the study also need to agree to take precautions to prevent pregnancy with a partner and not have intercourse with a pregnant woman during the study and for 7 months afterwards. Women should also not breastfeed during this time.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Am I aged between 18 and 65 (or 17 if in the military)?
- Do I have a suspected or confirmed case of Crimean-Congo or Lassa fever?
- Am I connected to military medical services, or can I access them?
- Do I agree to contraception if I'm a woman, or to prevent pregnancy with a partner if I'm a man, during and for 7 months after treatment?
- Do I not have a known bad reaction to Ribavirin?
- Is my general health, especially my blood count, suitable?
What does participation involve?
If you decide to take part, you would receive the medicine Ribavirin through a drip into your arm (intravenously). Before starting the medicine, you'll have a blood sample taken and checked. You'll need to agree to share information about any side effects you might experience while on the treatment.
After you have the first dose of Ribavirin, you'll need a follow-up visit around 14 days later (give or take 2 days), where blood and urine samples will be collected. You will also need to attend any other follow-up appointments your doctor thinks are necessary to check your health, especially for things like anaemia, which is when your blood doesn't have enough healthy red blood cells. The total duration of active treatment and close follow-up would likely be for the duration of your illness, with safety monitoring extending for 7 months after you finish taking Ribavirin.
Potential risks and benefits
Locations (1)
- Landstuhl Regional Medical CenterVerified postcodeLandstuhl, Germany
Common questions
What is Ribavirin?
Ribavirin is a medicine that works against some viruses. In this study, it's being given through a drip into a vein.
What are 'viral hemorrhagic fevers'?
These are serious illnesses caused by certain viruses, like Crimean-Congo hemorrhagic fever and Lassa fever, that can damage blood vessels.
Who can be in this study?
Mostly military-affiliated personnel and others who can access military medical facilities, aged 18-65 (or 17 if military), who are suspected of having or have confirmed CCHF or Lassa fever.
What does 'intravenous' mean?
It means the medicine is given directly into a vein, usually in your arm, through a drip.
Can I stop participating if I want to?
Yes, you can choose to stop being part of the study at any time, and it won't affect your medical care.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Interested in taking part?
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.